Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Cage Rattler who wrote (1015)	5/16/1998 1:03:00 PM
From: KAKALAK	Read Replies (1) \| Respond to of 2135

Just like ENMD, this stock is poised to rocket on Thursday the 21st of May. Advanced Viral Research Corp. Announces Extension of Research Agreement with National Cancer Institute Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that its Materials Transfer Agreement-Cooperative Research and Development Agreement (MTA-CRADA) with the National Cancer Institute (NCI) for research with ADVR's flagship drug, Reticulose, has been extended for one year, beginning March 4, 1998 and ending March 3, 1999. Reticulose is a non-toxic immunomodulator that has been shown to have a broad spectrum of antiviral therapeutic effects in patients. At the NCI, Reticulose is being used to study the basic mechanisms of immune responses. This scientific research is led by Dr. Howard Young, Section Chief in the Laboratory of Experimental Immunology at the NCI, an expert on interferon-gamma. Using kidney tumor model systems, Dr. Young is investigating the anti-tumor activity of Reticulose. In addition, Dr. Young and his colleagues will study the effects of Reticulose on inflammation associated with rheumatoid arthritis. "The extension of this collaborative agreement between Advanced Viral Research Corp. and one of the premier immunology research laboratories is an important event. We expect these research efforts to provide new insights into the therapeutic potentials, and uses of Reticulose while adding to our basic understanding of the workings of the immune system," stated Dr. Shalom Z. Hirschman, President and Chief Executive Officer of Advanced Viral Research Corp. NOTE the NCI's request to another year of RETICULOSE research after they already invested more than 1 year of manpower and money.